HUTCHMED (China) Limited

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of HUTCHMED (China) Limited (NASDAQ: HCM) resulting from allegations that HUTCHMED may have issued materially misleading business information to the investing public.

If you purchased HUTCHMED securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased HUTCHMED securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On May 2, 2022, before trading hours, HUTCHMED announced that the U.S. Food and Drug Administration (FDA) rejected HUTCHMED’s application seeking approval of surufatinib to treat certain neuroendocrine tumors, noting that the data submitted did not support an approval and a multi-regional clinical trial is required.

On this news, HUTCHMED’s American depositary share (ADS) price fell $2.86 per share, or 18%, to close at $12.23 per share on May 2, 2022.

Follow us on:
Company Name: HUTCHMED (China) Limited
Stock Symbol: HCM
Class Period: N/A
Court: N/A

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top